What are the common side effects of a biostimulator?
Swelling, bruising, redness, tenderness and sometimes itching, mostly in the first days. The US Food and Drug Administration lists bruising, redness, swelling, pain, tenderness, itching and rash as the common risks of dermal fillers, says most occur shortly after injection, and says many resolve in a few days to weeks. A biostimulator is an injected particle that prompts the skin to build collagen as the particle is absorbed over weeks to months. A 2025 guideline describes the mechanism as a sub-clinical inflammatory response, below the level of visible inflammation, that raises type I collagen at the injection site. The materials are described by class in the article on the biostimulator types.
Swelling can last longer than people expect. In a retrospective series of 1,111 treatments by one clinician using a polycaprolactone-based product, swelling beyond two weeks followed 4.5% of treatments, bruising 2.7% and a temporarily palpable lump 0.45%, and the longer swelling was linked to higher injection volume. A single clinician with a single product gives one data point, not a rate for a class.
What is a nodule, and how common is it?
A nodule is a small firm lump under the skin, from under 5 mm to over 10 mm, single or several. A 2026 scoping review of poly-L-lactic acid (PLLA) nodules calls this the most common presentation. When a lump has no heat, redness or tenderness, a 2025 guideline links it to product that has collected in one place, to placement, or to movement of the product, and says it appears within several months of injection as collagen forms.
For PLLA the scoping review gathers the numbers. One cohort of 130 people recorded nodules in 11, or 8.5%. Cohorts that used the older, less diluted preparation of 5 mL reported 8% to 14%. Safety data pooled from clinical trials gave 1.4%, and a prospective cohort of 98 people using 10 to 16 mL dilutions gave 2%, both as reported in the review. The review adds that rates differ with technique, dilution, follow-up time, the people studied and how a nodule is defined, and that many reports are case series with no denominator.
For calcium hydroxylapatite (CaHA), a 2026 review calls nodule formation one of the most frequently reported complications, and says most palpable nodules are self-limiting and cause no symptoms; it ties them to the particles and to shallow or mobile placement, and gives no overall rate. For poly-D,L-lactic acid (PDLLA), a 2025 guideline calls nodules and granulomas rare reports and gives no rate. For polycaprolactone, the 1,111-treatment series recorded no nodules or granulomas.
These figures cannot be lined up against each other. They come from different designs, follow-up times and definitions of a lump, and none is a head-to-head comparison. A rate belongs to the study that produced it, and nothing in this list shows one class to be safer than another.
Why do some lumps appear months later, and what is a granuloma?
Timing separates the types. The scoping review describes two peaks: early reactions at about four to eight weeks, usually from particles that have clumped or a limited tissue reaction, and later reactions after about six months, more often inflammatory or granulomatous. For practical use it splits them at three months. A Brazilian series of 55 complications after collagen biostimulators found that nodules were 89.1% of cases and that 60.0% appeared late, meaning more than a month after treatment. The cases were collected by questionnaire with no denominator, so the series shows what complications look like and not how often they happen.
A granuloma is a lump formed when immune cells wall off a foreign material. The 2025 guideline places granulomatous nodules at about six to 24 months after injection, firm and slowly growing, and describes a delayed hypersensitivity reaction, called angry red bumps, from three months to several years afterwards, usually across every area treated. The 2026 review puts delayed granulomas after CaHA at fewer than 1% of treated patients, and notes they can arise years later because the material lasts and cannot be broken down by an enzyme.
Infection looks different: a tender, red swelling within days to a few weeks, which the guideline says calls for antibiotics, ideally after a sample is taken for culture. The FDA also notes that swelling or redness near a filler can flare after a viral or bacterial illness, a vaccination or a dental procedure.
Can a biostimulator lump be dissolved like hyaluronic acid filler?
No. Hyaluronidase is an enzyme that digests hyaluronic acid, and none of the four materials is hyaluronic acid. The 2025 guideline says PDLLA nodules do not respond to straightforward enzymatic treatment, the 2026 review says CaHA cannot be enzymatically degraded, the polycaprolactone series says its product cannot be removed at once with an enzyme, and the PLLA review separates PLLA nodules from nodules caused by hyaluronic acid. In the Brazilian series hyaluronidase helped only where CaHA had been mixed with hyaluronic acid. The FDA states the general point: a filler not made of hyaluronic acid may be difficult or impossible to remove. The wider contrast is set out in dermal filler risks, and filler gone wrong covers the hyaluronic acid case where dissolving does work.
What is done instead depends on the lump. The PLLA review grades them: a single, small, non-inflammatory lump under 5 mm is met with reassurance, massage, warm compresses and watching; a persistent lump of 5 to 10 mm may be treated with an injected corticosteroid at four-week intervals; a strongly inflammatory lump may need combined treatment, antibiotics if infection is suspected, and in resistant cases a specialist and surgery. For CaHA, options include needle puncture, saline and excision, guided by ultrasound, and the evidence for sodium thiosulfate is anecdotal. The guideline adds a caution: other lumps, such as cysts, can mimic a nodule, and overtreating a minor lump has its own costs.
Do dilution, depth and massage make a difference?
They appear to, with limits. For PLLA, the scoping review says the early practice of 2 to 3 mL of water was linked to a high nodule rate, that current practice uses about 8 to 10 mL per vial for the face and 16 to 18 mL or more for the body, that the preparation is usually left to hydrate for 24 to 48 hours, and that injection into a deep subcutaneous plane is preferred. It also says the common five-minute, five-times-a-day, five-day massage routine has no robust randomised evidence of an independent preventive effect, and that dilution volume looks more important than massage alone. For CaHA, the 2026 review advises deep placement, conservative volumes and caution around the mouth and eyes, and notes that the area around the mouth is particularly susceptible to firm nodules while shallow placement can leave chalky deposits.
Technique is not the whole story. The Brazilian series found only one case injected at the wrong depth, and its authors concluded the problems seemed related more to the properties of the product than to technique. The fair reading is that careful preparation and placement lower the chance of a lump and cannot remove it, which is one reason to know in advance what the plan is if one appears.
What should I ask before biostimulator treatment in Malaysia?
Which material is it, and which product by name? Is that product registered in Malaysia, and can the registration be shown? Who is injecting, and are they a registered doctor? How is the product prepared, how long is it left to hydrate, and how deep does it go? What aftercare is advised, including whether to massage and for how long? What is the plan, and who is the contact, if a lump appears? The guide to checking an aesthetic doctor in Malaysia shows how to verify the doctor.
Say if any of these apply, because the FDA notes that safety is unknown in pregnancy, breastfeeding, under the age of 22 and in people prone to keloid or thick scarring. Where a biostimulator sits among other collagen options is compared in three roads to collagen.
When should I call the clinic?
Immediately for unusual pain, skin that turns white, grey or blue, a change in vision, or any sign of a stroke such as sudden trouble speaking or weakness in the face or limbs, during or shortly after treatment. The FDA lists these as reasons to seek urgent medical attention, because a filler can block a blood vessel.
Soon for a swelling that is red, warm or tender, a lump that is growing, or any new lump weeks or months later, including red bumps across the treated area. A small, firm lump with no pain can usually be reviewed at the next visit, but the clinic should know, since the right step depends on its size, its timing and whether it is inflamed. The PLLA review suggests reassessment at about four weeks, three months, six months and a year.
The honest complication
The evidence is thinner than the confidence of a brochure. The reviews rest mostly on case series and expert opinion, the nodule treatments have no high-quality randomised trials, several authors disclose ties to makers, and no overall rate across all four classes was found in what was read. Lumps are uncommon, usually manageable and sometimes slow to settle. They are also hard to reverse, which is why the first conversation matters more than the last one.
